These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 25861604)

  • 1. The importance of intake: a gut feeling.
    Gerritsen KG; Boer WH; Joles JA
    Ann Transl Med; 2015 Mar; 3(4):49. PubMed ID: 25861604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans.
    Spencer AG; Labonte ED; Rosenbaum DP; Plato CF; Carreras CW; Leadbetter MR; Kozuka K; Kohler J; Koo-McCoy S; He L; Bell N; Tabora J; Joly KM; Navre M; Jacobs JW; Charmot D
    Sci Transl Med; 2014 Mar; 6(227):227ra36. PubMed ID: 24622516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal Inhibition of Sodium-Hydrogen Exchanger 3 Reduces Phosphorus Absorption and Protects against Vascular Calcification in CKD.
    Labonté ED; Carreras CW; Leadbetter MR; Kozuka K; Kohler J; Koo-McCoy S; He L; Dy E; Black D; Zhong Z; Langsetmo I; Spencer AG; Bell N; Deshpande D; Navre M; Lewis JG; Jacobs JW; Charmot D
    J Am Soc Nephrol; 2015 May; 26(5):1138-49. PubMed ID: 25404658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers.
    Johansson S; Rosenbaum DP; Knutsson M; Leonsson-Zachrisson M
    Clin Exp Nephrol; 2017 Jun; 21(3):407-416. PubMed ID: 27368672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic inhibition of intestinal sodium uptake: a gut centric approach to sodium management.
    Spencer AG; Greasley PJ
    Curr Opin Nephrol Hypertens; 2015 Sep; 24(5):410-6. PubMed ID: 26197202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability.
    King AJ; Siegel M; He Y; Nie B; Wang J; Koo-McCoy S; Minassian NA; Jafri Q; Pan D; Kohler J; Kumaraswamy P; Kozuka K; Lewis JG; Dragoli D; Rosenbaum DP; O'Neill D; Plain A; Greasley PJ; Jönsson-Rylander AC; Karlsson D; Behrendt M; Strömstedt M; Ryden-Bergsten T; Knöpfel T; Pastor Arroyo EM; Hernando N; Marks J; Donowitz M; Wagner CA; Alexander RT; Caldwell JS
    Sci Transl Med; 2018 Aug; 10(456):. PubMed ID: 30158152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Treatments from Inhibition of the Intestinal Sodium-Hydrogen Exchanger 3.
    Kovesdy CP; Adebiyi A; Rosenbaum D; Jacobs JW; Quarles LD
    Int J Nephrol Renovasc Dis; 2021; 14():411-420. PubMed ID: 34880650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study.
    Johansson SA; Knutsson M; Leonsson-Zachrisson M; Rosenbaum DP
    Clin Pharmacol Drug Dev; 2017 Sep; 6(5):457-465. PubMed ID: 28339149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacokinetic evaluation of tenapanor for the treatment of irritable bowel syndrome with constipation: an update of the literature.
    Currò D; Ianiro G; Gasbarrini A
    Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):889-894. PubMed ID: 38108081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal salt wasting in mice lacking NHE3 Na+/H+ exchanger but not in mice lacking NHE2.
    Ledoussal C; Lorenz JN; Nieman ML; Soleimani M; Schultheis PJ; Shull GE
    Am J Physiol Renal Physiol; 2001 Oct; 281(4):F718-27. PubMed ID: 11553519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis.
    Block GA; Rosenbaum DP; Leonsson-Zachrisson M; Åstrand M; Johansson S; Knutsson M; Langkilde AM; Chertow GM
    J Am Soc Nephrol; 2017 Jun; 28(6):1933-1942. PubMed ID: 28159782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal NaCl transport in NHE2 and NHE3 knockout mice.
    Gawenis LR; Stien X; Shull GE; Schultheis PJ; Woo AL; Walker NM; Clarke LL
    Am J Physiol Gastrointest Liver Physiol; 2002 May; 282(5):G776-84. PubMed ID: 11960774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Tenapanor: A First-in-Class Minimally Systemic Inhibitor of Intestinal Na
    Jacobs JW; Leadbetter MR; Bell N; Koo-McCoy S; Carreras CW; He L; Kohler J; Kozuka K; Labonté ED; Navre M; Spencer AG; Charmot D
    ACS Med Chem Lett; 2022 Jul; 13(7):1043-1051. PubMed ID: 35859876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia.
    Nitta K; Itoyama S; Ikejiri K; Kinoshita J; Nakanishi K; Fukagawa M; Akizawa T
    Kidney Int Rep; 2023 Nov; 8(11):2243-2253. PubMed ID: 38025211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenapanor hydrochloride for the treatment of constipation-predominant irritable bowel syndrome.
    Zielińska M; Wasilewski A; Fichna J
    Expert Opin Investig Drugs; 2015; 24(8):1093-9. PubMed ID: 26065434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive and laxative effects by pharmacological inhibition of sodium-proton-exchanger subtype 3-mediated sodium absorption in the gut.
    Linz D; Wirth K; Linz W; Heuer HO; Frick W; Hofmeister A; Heinelt U; Arndt P; Schwahn U; Böhm M; Ruetten H
    Hypertension; 2012 Dec; 60(6):1560-7. PubMed ID: 23108657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial.
    Block GA; Rosenbaum DP; Yan A; Chertow GM
    J Am Soc Nephrol; 2019 Apr; 30(4):641-652. PubMed ID: 30846557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological inhibition of sodium-proton-exchanger subtype 3-mediated sodium absorption in the gut reduces atrial fibrillation susceptibility in obese spontaneously hypertensive rats.
    Linz B; Hohl M; Mishima R; Saljic A; Lau DH; Jespersen T; Schotten U; Sanders P; Linz D
    Int J Cardiol Heart Vasc; 2020 Jun; 28():100534. PubMed ID: 32462076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Myth of Water and Salt: From Aquaretics to Tenapanor.
    Visconti L; Cernaro V; Calimeri S; Lacquaniti A; De Gregorio F; Ricciardi CA; Lacava V; Santoro D; Buemi M
    J Ren Nutr; 2018 Mar; 28(2):73-82. PubMed ID: 29146141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical and Healthy Volunteer Studies of Potential Drug-Drug Interactions Between Tenapanor and Phosphate Binders.
    Johansson S; Leonsson-Zachrisson M; Knutsson M; Spencer AG; Labonté ED; Deshpande D; Kohler J; Kozuka K; Charmot D; Rosenbaum DP
    Clin Pharmacol Drug Dev; 2017 Sep; 6(5):448-456. PubMed ID: 27654985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.